Loading viewer...
investor_presentation
Format: PDF investor_presentation
ARK Investment Management's 2019 research report exploring CRISPR gene-editing technology as a revolutionary approach to treating genetic diseases including sickle cell anemia, cystic fibrosis, and childhood blindness. The analysis highlights early clinical trials underway in the United States and projects significant market opportunities driven by the technology's ease of use, cost-efficiency, and safety profile.
investor_presentation
15 Pages
Hansa Biopharma
Texas Pacific Land TPL Produced Water Desalination 2024
investor_presentationinvestor_presentation
15 Pages
Texas Pacific Land Corporation
investor_presentation
Camtek